Novartis has reported that its experimental drug ianalumab met the primary goal in a phase 3 trial for primary immune thrombocytopenia (ITP), a rare autoimmune condition where the immune system destroys platelets, increasing the risk of bleeding and fatigue. The study, VAYHIT2, investigated ianalumab alongside eltrombopag in patients whose disease had not responded to corticosteroids […]